|January 31, 2003
|Hemispherx Presents New Data on Long-term, Post-trial Effects of RNA-based Ampligen(R) for Treatment for Chronic Fatigue Syndrome
|At Sixth Annual American Association of Chronic Fatigue Syndrome Conference January 31 - February 2, Chantilly, Virginia
Philadelphia, PA, Friday, January 31, 2003: Hemispherx Biopharma Inc. (Amex: HEB - News) presents new data January 31 on the long-term, post-trial effects of RNA-based Ampligen®, an experimental drug, for potential treatment of CFS, at the Sixth Annual American Association of Chronic Fatigue Syndrome Conference. Hemispherx Medical Director David R. Strayer, M.D. will present the data at the January 31 - February 2 conference in Chantilly, Virginia.
" ... analysis of 81 patients from expanded access treatment protocol ... shows changes in physical performance, cognitive function, vitality, and physical activity."
* 80% of patients who complete the 24-week study continue with Ampligen
treatments on a cost-recovery basis.
* FDA has authorized availability of Ampligen(R) on this emergency
treatment basis, and given it "orphan drug" status. Ampligen is made
by Hemispherx http://www.hemispherx.net
* The fully enrolled, Phase III clinical trial is ongoing at eight sites
nationwide. Study is confirmatory, randomized, double-blinded and
The experimental compound, RNA-based Ampligen® acts by a mechanism proposed to stimulate the body's own immune defenses. More than 50,000 doses of Ampligen® have been administered in studies at 20+ clinical trial sites. Ampligen® is an experimental, investigational drug and, as such, is not designated as safe or effective by a regulatory authority for general use and is legally available only through clinical trials.
Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the Immune system including, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. For more information visit the company's Web sit at http://www.hemispherx.net .
Hemispherx Biopharma, Inc., Investor Relations
(518) 398-6222, Fax: (518) 398-6223
Wesley Staton, MRB Institutional Investors
(212) 495-0200, Fax: (212) 495-0746
HEB's Web Site: www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.